The following article features coverage from the 2020 Genitourinary Cancers Symposium meeting. Click here to read more of Renal and Urology News’ conference coverage.

SAN FRANCISCO—Men diagnosed with a primary testicular germ cell tumor (TGCT) are at lower risk of a metachronous contralateral testicular germ cell tumor (CTGCT) if they were treated with chemotherapy for their primary tumor, data presented at the 2020 Genitourinary Cancers Symposium suggest. This effect is dose-dependent as the risk of CTGCT decreases with each additional chemotherapy cycle.

In a study of 4755 men diagnosed with primary TGCT from 1989 to 2007 (seminoma in 54.9% and nonseminomatous in 45.1%), a metachronous CTGCT was diagnosed in 136 men after a median follow-up of 17 years, Joost Blok, MD, of The Netherlands Cancer Institute in Amsterdam, and colleagues reported. The median interval until CTGCT diagnosis was 6.1 years (range 0.8 to 19.7 years).

Continue Reading

On multivariate analysis, the risk of CTGCT was a significant 58% lower after nonseminomatous germ cell tumor (NSGCT) compared with seminoma. The risk decreased significantly by 26% with each additional cycle of chemotherapy. The risk also decreased with higher age at primary diagnosis.

The overall 20-year cumulative incidence was 3.4%, and was significantly higher after seminoma than NSGCT: 4% vs 2.6%. Compared with the general population, men with primary TGCT were nearly 15 times more likely to experience a CTGCT, according to the investigators. The risk of CTGCT was 22 times and 8.6 times higher for men with seminoma and NSGCT tumors.

The patients had a median age of 33 years at the time they were diagnosed with primary TGCT. Of the 4755 men, 1047 (22%) were treated with platinum-based chemotherapy for their primary TGCT.

Read more of our coverage of the 2020 Genitourinary Cancers Symposium by visiting the conference page.

Related Articles


Blok JM, Groot HJ, Huele EH, et al. Incidence and risk factors for contralateral testicular tumor. Presented at the 2020 Genitourinary Cancers Symposium held February 13 to 15 in San Francisco. Abstract 419.